Nuclear Medicine
A review of modern imaging landscape for prostate cancer: a comprehensive clinical guide
9 May, 2023 | 14:34h | UTC
Metomidate PET-CT vs. adrenal vein sampling for diagnosing surgically curable primary aldosteronism: a prospective, within-patient trial
19 Jan, 2023 | 14:19h | UTCNews Release: Ten-minute scan enables detection and cure of the commonest cause of high blood pressure – Queen Mary University of London
Guideline | Use of [18F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors
19 Jan, 2023 | 14:13h | UTC
EANM practice guideline for quantitative SPECT-CT.
13 Dec, 2022 | 14:26h | UTC
18F-sodium fluoride PET–CT vs. 99mTc bone scintigraphy with SPECT in patients with prostate cancer or breast cancer.
22 Nov, 2022 | 13:09h | UTCIntra-individual comparison of 18F-sodium fluoride PET–CT and 99mTc bone scintigraphy with SPECT in patients with prostate cancer or breast cancer at high risk for skeletal metastases (MITNEC-A1): a multicentre, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)
Commentary: 18F-NaF PET-CT More Accurate Than 99mTc-MDP SPECT for Detecting Bone Metastasis – Cancer Therapy Advisor
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given radioisotope therapy for prostate cancer.
22 Nov, 2022 | 12:56h | UTCPSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial – The Lancet Oncology (link to abstract – $ for full-text)
Commentary: PSMA-PET SUVmean Linked With Favorable Response to 177Lu-PSMA-617 in mCRPC – Targeted Oncology
Consensus Statements | Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in patients with prostate cancer and with respect to [177Lu] Lu-PSMA radioligand therapy.
6 Jul, 2022 | 11:39h | UTCRCT | CT vs. [18F]FDG-PET-CT for persistent or recurrent neutropenic fever in high-risk patients.
4 Jul, 2022 | 12:21h | UTC[18F]FDG-PET-CT compared with CT for persistent or recurrent neutropenic fever in high-risk patients (PIPPIN): a multicentre, open-label, phase 3, randomised, controlled trial – The Lancet Haematology (link to abstract – $ for full-text)
Commentary on Twitter
NEW research: [18F]FDG-PET-CT resulted in more frequent antimicrobial rationalisation than CT in patients w/ haem diseases & persistent/recurrent high-risk neutropenic fever after chemotherapy. Results of the ph3 RCT PIPPIN #radonc #hemonc https://t.co/isOPFZVVpY pic.twitter.com/PVd8yFy7Ck
— The Lancet Haematology (@TheLancetHaem) June 29, 2022
M-A: Accuracy of Fluorodeoxyglucose Positron Emission Tomography/ Computerized Tomography for diagnosing periprosthetic joint infections.
21 Jun, 2022 | 10:38h | UTC
Position Paper | Individualized treatment of differentiated thyroid cancer: The value of surgery in combination with radioiodine imaging and therapy.
24 Mar, 2022 | 08:34h | UTC
Multicenter comparative accuracy trial: Dynamic contrast-enhanced CT vs. positron emission tomography CT to characterize solitary pulmonary nodules.
16 Mar, 2022 | 08:51h | UTCDownload: Full Report
Review | Molecular imaging in oncology: Current impact and future directions.
11 Feb, 2022 | 08:12h | UTC
Prolonged follow-up of RCT: Emission Tomography–driven strategy in advanced Hodgkin Lymphoma.
19 Jan, 2022 | 08:16h | UTCPositron Emission Tomography–Driven Strategy in Advanced Hodgkin Lymphoma: Prolonged Follow-Up of the AHL2011 Phase III Lymphoma Study Association Study – Journal of Clinical Oncology (link to abstract – $ for full-text)
Consensus Document: Non-invasive imaging in coronary syndromes.
10 Nov, 2021 | 07:11h | UTC
Consensus Document: Multimodality imaging in patients with heart failure and preserved ejection fraction.
10 Nov, 2021 | 07:09h | UTC
M-A: Direct comparison of preoperative imaging modalities for localization of primary hyperparathyroidism – “choline PET-CT would be the best preoperative imaging modality for localization of primary hyperparathyroidism”.
6 Jun, 2021 | 23:40h | UTCJAMA Otolaryngology – Head & Neck Surgery (free for a limited period)
Invited commentary: Localization Studies for Parathyroid Surgery (free for a limited period)
RCT: Inclusion of 18F-fluciclovine-PET/CT imaging to guide postprostatectomy salvage radiotherapy in patients with prostate cancer may improve survival free from biochemical recurrence or persistence.
10 May, 2021 | 00:46h | UTC18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2/3 randomised controlled trial – The Lancet (link to abstract – $ for full-text)
PET imaging reveals which breast cancer patients won’t respond to hormone therapy
10 Feb, 2021 | 01:09h | UTC